{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 38,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a combination of a checklist for past achievements and a timeline arrow for future goals.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/30",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.34,
        "y": 0.16
      },
      "kind": "diagram",
      "text": "Initiate Phase 2 trial in (Adjuvant Maintenance) NSCLC; Enter additional regional development & commercial partnership(s) and platform collaborations; Initiate Phase 1/2 trial in recurrent ovarian cancer (IV route); Initiate Ph1b/2 trial of V2ACT",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a183f170-a29b-43d3-93d1-d55c80b4d5dd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.28,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "list",
      "text": "Executed on go public strategy and follow on with $60M raised; Initiation of Phase 3 Trial in PRROC; Phase 2 results published in JAMA Oncology; Collaboration and License agreement with Newsoara; Initiation of Phase 1b/2 trial in recurrent SCLC (China); Issuance of V2ACT US Patent",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52cd0073-b72d-44cd-a72f-009237f48276",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Genelux Has Executed on Multiple Milestones and is Positioned for the Future",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d43267ac-f578-4b2f-917f-67102ee88037",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "4af8119b-a652-441d-a54a-8a8a0b85849f",
      "evidence": "The slide uses a visual arrow to represent future milestones over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 38,
      "from": 10,
      "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}